Promising combo aims to boost Cancer-Free survival in head and neck cancer
NCT ID NCT07524452
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is testing whether adding a targeted drug (becotatug vedotin) to standard immunotherapy (a PD-1 inhibitor) before and after surgery can help people with a certain type of head and neck cancer live longer without the cancer coming back. About 430 adults with EGFR-positive, CPS≥1 resectable locally advanced head and neck squamous cell carcinoma will be randomly assigned to receive the combination or immunotherapy alone. The main goal is to see if the combo improves event-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
becotatug vedotin (a targeted drug) plus pucotenlimab (an immunotherapy)
What this could lead to
If successful, this combination could become a new standard treatment before and after surgery for certain head and neck cancers, potentially improving the chance of staying cancer-free.
What could go wrong
This is still an experimental approach; the added drug may cause more side effects and it's unknown if it will truly improve outcomes over the immunotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fifth Affiliated Hospital,Sun Yat-sen University
RECRUITINGZhuhai, Guangdong, 519099, China
Contact Phone: •••-•••-•••• Email: •••••@•••••